{'fraction_non_alphanumeric': 0.036455059710873663, 'fraction_numerical': 0.034569453174104335, 'mean_word_length': 4.852941176470588, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Pharmacokinetics of Ritanserin in Patients Undergoing Hemodialysis

The pharmacokinetics of ritanserin were studied in five patients with chronic renal insufficiency and who were undergoing periodic hemodialysis. Immediately after breakfast, a single 10‐mg ritanserin tablet was administered to each patient on a day that they did not undergo dialysis. Plasma ritanserin levels were measured by a specific high‐performance liquid chromatographic assay sensitive to 2 ng/mL plasma. After the oral 10‐mg dose, the average time to reach the peak plasma concentration, Tmax, was 4.4 ± 2.2 hours in these uremic patients, with a range of 2 to 8 hours. The average peak plasma concentration was 73.6 ± 26.9 ng/mL (range: 54.6–120.0 ng/mL). Compared with a previous study in healthy volunteers, the uremic patients had a slower absorption profile, with a 39% reduction in peak plasma concentration and a mean delay of 2.5 hours in Tmax. The mean area under the plasma concentration—time curve for ritanserin (2031 ± 636 ng·hr/mL) was 47% lower compared with that in healthy volunteers (3667 ± 1413 ng·hr/mL). The observed delayed and lower ritanserin absorption in these uremic patients may be caused by the chronic use of antacids such as aluminum hydroxide and calcium carbonate in all patients and/or by concurrent pathologic changes in the gastrointestinal mucosa of these patients. The regular hemodialysis sessions every 2–3 days did not affect the elimination rate of ritanserin, as the terminal half‐life in these patients (39 ± 23 hr) is similar to that in healthy volunteers (41 ± 14 hr).